An update on immunotherapy with PD-1 and PD-L1 blockade

키워드

참고문헌 (64)

1. 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
2. Hamid O, "Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001", Ann Oncol, 30, pp.582~588 (2019)
3. Sanmamed MF, "A paradigm shift in cancer immunotherapy : from enhancement to normalization", Cell, 175, pp.313~326 (2018)
4. Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
5. Vesely MD, "Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy", Ann N Y Acad Sci, 1284, pp.1~5 (2013)
6. Korman AJ, "Checkpoint blockade in cancer immunotherapy", Adv Immunol, 90, pp.297~339 (2006)
7. Wing K, "CTLA-4 control over Foxp3+ regulatory T cell function", Science, 322, pp.271~275 (2008)
8. Dong H, "Tumor-associated B7-H1 promotes T-cell apoptosis : a potential mechanism of immune evasion", Nat Med, 8, pp.793~800 (2002)
9. Vesely MD, "Natural innate and adaptive immunity to cancer", Annu Rev Immunol, 29, pp.235~271 (2011)
10. Radoja S, "Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo", J Immunol, 164, pp.2619~2628 (2000)
11. Francisco LM, "PD-L1 regulates the development, maintenance, and function of induced regulatory T cells", J Exp Med, 206, pp.3015~3029 (2009)
12. Zou W, "Inhibitory B7-family molecules in the tumour microenvironment", Nat Rev Immunol, 8, pp.467~477 (2008)
13. Latchman Y, "PD-L2 is a second ligand for PD-1 and inhibits T cell activation", Nat Immunol, 2, pp.261~268 (2001)
14. Dong H, "B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion", Nat Med, 5, pp.1365~1369 (1999)
15. Wang X, "PD-L1 expression in human cancers and its association with clinical outcomes", Onco Targets Ther, 9, pp.5023~5039 (2016)
16. Iwai Y, "Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade", Proc Natl Acad Sci U S A, 99, pp.12293~12297 (2002)
17. Robert C, "Nivolumab in previously untreated melanoma without BRAF mutation", N Engl J Med, 372, pp.320~330 (2015)
18. Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
19. Ferris RL, "Nivolumab for recurrent squamous-cell carcinoma of the head and neck", N Engl J Med, 375, pp.1856~1867 (2016)
20. Ansell SM, "PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma", N Engl J Med, 372, pp.311~319 (2015)
21. Kang YK, "Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet, 390, pp.2461~2471 (2017)
22. Overman MJ, "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study", Lancet Oncol, 18, pp.1182~1191 (2017)
23. Sharma P, "Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial", Lancet Oncol, 18, pp.312~322 (2017)
24. El-Khoueiry AB, "Phase I", II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma(HCC) : CA209-040, 2015, pp.33(Suppl), LBA101~
25. Motzer RJ, "Nivolumab versus everolimus in advanced renal-cell carcinoma", N Engl J Med, 373, pp.1803~1813 (2015)
26. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
27. Ribas A, "Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial", Lancet Oncol, 16, pp.908~918 (2015)
28. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
29. Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
30. Chen R, "Phase II study of the efficacy and safety of pembrolizumab for relapsed", refractory classic Hodgkin lymphoma, 2017, pp.35, 2125~2132
31. Bellmunt J, "Pembrolizumab as second-line therapy for advanced urothelial carcinoma", N Engl J Med, 376, pp.1015~1026 (2017)
32. Mehra R, "Efficacy and safety of pembrolizumab in recurrent", metastatic head and neck squamous cell carcinoma : pooled analyses after long-term follow-up in KEYNOTE-012, 2018, pp.119, 153~159
33. Cortes J, "Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE -355): a randomised, placebo-controlled, double-blind, phase 3clinical trial", Lancet, 396, pp.1817~1828 (2020)
34. Schmid P, "Pembrolizumab for early triple-negative breast cancer", N Engl J Med, 382, pp.810~821 (2020)
35. Rosenberg JE, "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm, multicentre, phase 2 trial", Lancet, 387, pp.1909~1920 (2016)
36. Balar AV, "Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial", Lancet, 389, pp.67~76 (2017)
37. Herbst RS, "Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC", N Engl J Med, 383, pp.1328~1339 (2020)
38. Fehrenbacher L, "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial", Lancet, 387, pp.1837~1846 (2016)
39. Yun S, "Targeting immune checkpoints in unresectable metastatic cutaneous melanoma : a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials", Cancer Med, 5, pp.1481~1491 (2016)
40. Lu J, "Clinical evaluation of compounds targeting PD-1", PD-L1 pathway for cancer immunotherapy, 2015, pp.21, 451~467
41. Gibney GT, "Predictive biomarkers for checkpoint inhibitor-based immunotherapy", Lancet Oncol, 17, pp.e542~51 (2016)
42. Tumeh PC, "PD-1 blockade induces responses by inhibiting adaptive immune resistance", Nature, 515, pp.568~571 (2014)
43. Samstein RM, "Tumor mutational load predicts survival after immunotherapy across multiple cancer types", Nat Genet, 51, pp.202~206 (2019)
44. Snyder A, "Genetic basis for clinical response to CTLA-4blockade in melanoma", N Engl J Med, 371, pp.2189~2199 (2014)
45. Van Allen EM, "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma", Science, 350, pp.207~211 (2015)
46. Champiat S, "Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC", J Thorac Oncol, 9, pp.144~153 (2014)
47. Mantovani A, "Tumour immunity : effector response to tumour and role of the microenvironment", Lancet, 371, pp.771~783 (2008)
48. Gandhi L, "Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer", N Engl J Med, 378, pp.2078~2092 (2018)
49. Paz-Ares L, "Pembrolizumab plus chemotherapy for squamous nonsmall-cell lung cancer", N Engl J Med, 379, pp.2040~2051 (2018)
50. Schmid P, "Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer", N Engl J Med, 379, pp.2108~2121 (2018)
51. Horn L, "First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer", N Engl J Med, 379, pp.2220~2229 (2018)
52. Paz-Ares L, "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage smallcell lung cancer (CASPIAN): a randomised, controlled, openlabel, phase 3 trial", Lancet, 394, pp.1929~1939 (2019)
53. Galsky MD, "Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 395, pp.1547~1557 (2020)
54. Powles T, "Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial", Lancet Oncol, 22, pp.931~945 (2021)
55. Janjigian YY, "First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial", Lancet, 398, pp.27~40 (2021)
56. Rini BI, "Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma", N Engl J Med, 380, pp.1116~1127 (2019)
57. Powles T, "Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial", Lancet Oncol, 21, pp.1563~1573 (2020)
58. Motzer R, "Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma", N Engl J Med, 384, pp.1289~1300 (2021)
59. Choueiri TK, "Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma", N Engl J Med, 384, pp.829~841 (2021)
60. Makker V, "A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer", J Clin Oncol, 37(15 Suppl), pp.5607~ (2019), TPS5607
61. Dickler MN, "MONARCH 1, a phase II study of abemaciclib, a CDK4and CDK6 inhibitor, as a single agent, in patients with refractory HR+", HER2- metastatic breast cancer, 2017, pp.23, 5218~5224
62. Diaz LA, "Pembrolizumab in microsatellite instability high cancers : updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies", Ann Oncol, 30(Suppl 5), pp.v475~ (2019)
63. Konstantinopoulos PA, "Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma", JAMA Oncol, 5, pp.1141~1149 (2019)
64. Vinayak S, "Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer", JAMA Oncol, 5, pp.1132~1140 (2019)

관련 논문AI추천